^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Preclinical evaluation of WXSH0011, a selective small molecule dual inhibitor of FGFR/c-Met.

Published date:
05/28/2020
Excerpt:
The antitumor activity of WXSH0011 was evaluated in vivo cell derived-xenograft (CDX) models of Gastric Cancer SNU-16 and HCC Hep3B….WXSH0011 inhibited cell proliferation in FGFR overexpressed NCl-H1581, SNU-16, RT112/84, Hep3B with IC50 10 nM, 3 nM, 2 nM, 63 nM,...
DOI:
10.1200/JCO.2020.38.15_suppl.e15641